Mostrando 10 resultados de: 13
Filtros aplicados
Publisher
Cancer Biology and Therapy(3)
Cancer Biotherapy and Radiopharmaceuticals(1)
Clinical Nuclear Medicine(1)
Clinical and Translational Immunology(1)
Frontiers in Oncology(1)
Área temáticas
Enfermedades(13)
Farmacología y terapéutica(9)
Cirugía y especialidades médicas afines(1)
Fisiología humana(1)
Fisiología y materias afines(1)
Objetivos de Desarrollo Sostenible
ODS 10: Reducción de las desigualdades(13)
ODS 3: Salud y bienestar(13)
ODS 17: Alianzas para lograr los objetivos(11)
ODS 5: Igualdad de género(1)
ODS 9: Industria, innovación e infraestructura(1)
Origen
scopus(13)
A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer
ArticleAbstract: Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has bPalabras claves:Advanced cervical cancer, eGFR, Monoclonal antibody, nimotuzumab, Pilot studyAutores:Astudillo H., Avila S., Bazán B., Bojalil R., Cetina L., Charco E., Coronel J., Dueñas-Gonzãlez A., Jiménez-Lima R., Ramos M., Tania Crombet, Zapata S.Fuentes:scopusAn anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania CrombetFuentes:scopusAntiproliferative, antiangiogenic and proapoptotic activity of H-R3: A humanized anti-EGFR antibody
ArticleAbstract: The epidermal growth factor receptor (EGFR) proto-oncogene is frequently overexpressed in tumors ofPalabras claves:Angiogenesis, Epidermal growth factor receptor (EGFR), H-R3, Monoclonal antibody, Signal inhibitorsAutores:Pérez R., Rak J., Tania Crombet, Viloria-Petit A.Fuentes:scopusImmunoscintigraphy with <sup>99m</sup>Tc-nimotuzumab for planning immunotherapy in patients with bone metastases due to prostate cancer
ArticleAbstract: Detection of bone metastases indicates poor prognosis for patients with prostate cancer. The immunotPalabras claves:Bone metastases, Immunoscintigraphy, Monoclonal antibody, nimotuzumab, Prostate cancerAutores:Batista J.F., Perera A., Prats A., Quián Y.P., Tania CrombetFuentes:scopusPharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer
ArticleAbstract: Epidermal growth factor receptor (EGFR) overexpression has been detected in many tumors of epitheliaPalabras claves:Epidermal growth factor receptor, Monoclonal antibody, Phase I clinical trialAutores:Catala M., Iznaga N., Lage Davila A., Neninger Vinageras E., Perera A., Pérez R., Solano M., Tania Crombet, Torres F., Torres L., Torres O.Fuentes:scopusPhase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor
ArticleAbstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)Palabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitorsAutores:Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.Fuentes:scopusNimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
ArticleAbstract: EGFR signaling is an important regulator of SARS-CoV induced lung damage, inflammation and fibrosis.Palabras claves:brief research report nimotuzumab, covid-19, eGFR, FIBROSIS, inflammation, Monoclonal antibody, SARS-COV-2Autores:Batista D., Cabrera L., Diaz H., Domeq M., Gorte A., Hernández A., Hernández R., Jiménez J., Jova J.H., Luaces P.L.o., Martínez A., Medel L., Pérez Ruiz L., Porto L., Ramos M., Saavedra Hernández D., Sánchez L., Tania Crombet, Travieso N., Troche M., Valdés L., Valls A.R.Fuentes:scopusNimotuzumab for Patients With Inoperable Cancer of the Head and Neck
ReviewAbstract: EGFR activation induces cell proliferation, neoformation of blood vessels, survival, and metastasisPalabras claves:eGFR, head and neck, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Iznaga-Escobar N., Mazorra Z., Mestre Fernández B., Tania CrombetFuentes:scopusNimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience
ArticleAbstract: Nimotuzumab, a humanized antibody targeting epidermal growth factor receptor, has potent anti-prolifPalabras claves:Anaplastic astrocytoma, glioblastoma multiforme, High grade glioma, Monoclonal antibody, nimotuzumab, RadiotherapyAutores:Alert J., Chon I., Jorrín E., Luaces P.L.o., Marinello J.J.u., Miranda N., Solomón M.T.e., Tania CrombetFuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopus